ViiV Healthcare, GSK’s worldwide HIV specialist, recently released the positive results from its 41-week Phase IIa ÉCLAIR study to determine the tolerability, safety, satisfaction and dosing of an investigational monotherapy for potential HIV patients.
The treatment, which is long-acting, injectable cabotegravir (an integrase strand transfer inhibitor), is meant to treat pre-exposure prophylaxis (PrEP) among healthy adult males who are not infected with HIV but are at an increased risk for contracting the virus.
The results from the study suggest that cabotegravir should be advanced to the next phase: creating a possible drug to prevent HIV infections.
“There are more than 36 million people worldwide living with HIV today and, despite considerable progress made in the fight against HIV, infections are still increasing in parts of the world,” ViiV
Chief Scientific and Medical Officer
John Pottage said. “Preventative measures like PrEP could play an important role in reducing the number of new infections and help contribute to the goal of ending the global AIDS epidemic. We are encouraged by these first results from the ECLAIR study and look forward to understanding the potential efficacy and broader safety profile of cabotegravir in the PrEP setting as we move into phase III development later this year.”
